Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Identification of Antifungal Compounds against Multidrug-Resistant Candida auris Utilizing a High-Throughput Drug-Repurposing Screen

Identification of Antifungal Compounds against Multidrug-Resistant Candida auris Utilizing a... Downloaded from http://aac.asm.org/ on April 14, 2021 by guest SUSCEPTIBILITY Identification of Antifungal Compounds against Multidrug- Resistant Candida auris Utilizing a High-Throughput Drug- Repurposing Screen a b a c b b b Yu-Shan Cheng, Jose Santinni Roma, Min Shen, Caroline Mota Fernandes, Patricia S. Tsang, He Eun Forbes, Helena Boshoff, c c,d,e a b Cristina Lazzarini, Maurizio Del Poeta, Wei Zheng, Peter R. Williamson National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, USA Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA Department of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, USA Division of Infectious Diseases, Stony Brook University, Stony Brook, New York, USA Veterans Affairs Medical Center, Northport, New York, USA ABSTRACT Candida auris is an emerging fatal fungal infection that has resulted in several outbreaks in hospitals and care facilities. Current treatment options are lim- ited by the development of drug resistance. Identification of new pharmaceuticals to combat these drug-resistant infections will thus be required to overcome this unmet medical need. We have established a bioluminescent ATP-based assay to identify new compounds and potential drug combinations showing effective growth http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Antimicrobial Agents and Chemotherapy American Society For Microbiology

Identification of Antifungal Compounds against Multidrug-Resistant Candida auris Utilizing a High-Throughput Drug-Repurposing Screen

Identification of Antifungal Compounds against Multidrug-Resistant Candida auris Utilizing a High-Throughput Drug-Repurposing Screen

Antimicrobial Agents and Chemotherapy , Volume 65 (4) – Mar 18, 2021

Abstract

Downloaded from http://aac.asm.org/ on April 14, 2021 by guest SUSCEPTIBILITY Identification of Antifungal Compounds against Multidrug- Resistant Candida auris Utilizing a High-Throughput Drug- Repurposing Screen a b a c b b b Yu-Shan Cheng, Jose Santinni Roma, Min Shen, Caroline Mota Fernandes, Patricia S. Tsang, He Eun Forbes, Helena Boshoff, c c,d,e a b Cristina Lazzarini, Maurizio Del Poeta, Wei Zheng, Peter R. Williamson National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, USA Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA Department of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, USA Division of Infectious Diseases, Stony Brook University, Stony Brook, New York, USA Veterans Affairs Medical Center, Northport, New York, USA ABSTRACT Candida auris is an emerging fatal fungal infection that has resulted in several outbreaks in hospitals and care facilities. Current treatment options are lim- ited by the development of drug resistance. Identification of new pharmaceuticals to combat these drug-resistant infections will thus be required to overcome this unmet medical need. We have established a bioluminescent ATP-based assay to identify new compounds and potential drug combinations showing effective growth

Loading next page...
 
/lp/american-society-for-microbiology/identification-of-antifungal-compounds-against-multidrug-resistant-GPWzOZA1ji

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Society For Microbiology
Copyright
Copyright © 2021 American Society for Microbiology
ISSN
0066-4804
eISSN
1098-6596
DOI
10.1128/aac.01305-20
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://aac.asm.org/ on April 14, 2021 by guest SUSCEPTIBILITY Identification of Antifungal Compounds against Multidrug- Resistant Candida auris Utilizing a High-Throughput Drug- Repurposing Screen a b a c b b b Yu-Shan Cheng, Jose Santinni Roma, Min Shen, Caroline Mota Fernandes, Patricia S. Tsang, He Eun Forbes, Helena Boshoff, c c,d,e a b Cristina Lazzarini, Maurizio Del Poeta, Wei Zheng, Peter R. Williamson National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, USA Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA Department of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, USA Division of Infectious Diseases, Stony Brook University, Stony Brook, New York, USA Veterans Affairs Medical Center, Northport, New York, USA ABSTRACT Candida auris is an emerging fatal fungal infection that has resulted in several outbreaks in hospitals and care facilities. Current treatment options are lim- ited by the development of drug resistance. Identification of new pharmaceuticals to combat these drug-resistant infections will thus be required to overcome this unmet medical need. We have established a bioluminescent ATP-based assay to identify new compounds and potential drug combinations showing effective growth

Journal

Antimicrobial Agents and ChemotherapyAmerican Society For Microbiology

Published: Mar 18, 2021

References